Venture Capital

A new oral drug could eliminate the dangerous side effects of CAR T-Cell therapy, potentially making the breakthrough cancer treatment safer and more accessible.

Allbirds co-founder Joey Zwillinger is applying consumer tech disruption to women's health. Can Biologica's science-backed model reshape a stagnant market?

With a $12M boost from a16z, Pryzm's AI is tackling the Pentagon's $900B procurement problem. Can software fix bureaucracy and secure America's edge?

With a $24M Series A, AnySignal is modernizing mission-critical infrastructure. How will its software-defined radios reshape space and national security?

Same-day delivery is no longer just about speed. It's enabling DTC brands to sell what was once unshippable, transforming product lines and logistics.

New data reveals a massive, quiet market for spiritual wellness among younger generations. Investors are taking note of platforms monetizing this trend.

A new partnership aims to turn dusty tape libraries into revenue streams using AI, marking a major strategic shift for a legacy hardware maker.

Law firm Gunderson Dettmer's major partner expansion signals confidence not in the whole market, but in the AI-driven, high-value core of the venture economy.

PTC launches its Arena AI Engine to automate compliance and document review, offering a strategic advantage for complex defense and aerospace supply chains.

A new patent for reactivated carbon technology offers a circular solution to destroy "forever chemicals," promising a reliable path for U.S. water safety.

Beyond transmissions, Allison's deep investment in India is a blueprint for global firms fueling defense, mining, and export growth. Here's why it matters.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Beyond e-commerce, GigaCloud's massive new NJ facility signals a strategic move to fortify trans-pacific supply lines for large goods, impacting US economic competitiveness.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

With a $140M war chest, Empower Semiconductor expands to Silicon Valley and Munich, betting its vertical power tech can solve the energy crisis facing AI.

After a financial tightrope walk, Actelis Networks is back in Nasdaq's good graces. But the real story is its mission to secure our future's IoT.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.